RxDoctor Payments Data

Philip Johnson, MD

Internal Medicine · Houston, TXNPI 1063430445

Payments from drug & device makers

$133,604in general payments, 2019–2025

Across 46 payments — averaging $2904.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$68K
  • Viiv Healthcare Company$65K
  • Merck$185
  • Theratechnologies Inc.$38
  • Alkermes, Inc.$24
  • Shionogi Inc$12

What the payments were for

  • Food & beverage$24895%
  • Education$125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead10$68,075
Viiv Healthcare Company22$65,269
Merck10$185
Theratechnologies Inc.2$38
Alkermes, Inc.1$24
Shionogi Inc1$12

How this compares

$133,604 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$70,719
Medicare patients
239
Services billed
866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala277$1,101,626
TriumeqAbacavir/Dolutegravir/Lamivudi93$360,736
TivicayDolutegravir Sodium131$295,162
GenvoyaElviteg/Cob/Emtri/Tenof Alafen52$184,291
PrezcobixDarunavir/Cobicistat60$166,182
DovatoDolutegravir Sodium/Lamivudine47$130,400
JulucaDolutegravir/Rilpivirine33$110,618
StribildElviteg/Cob/Emtri/Tenofo Disop24$106,051
JardianceEmpagliflozin96$100,397
OzempicSemaglutide71$84,492
DescovyEmtricitabine/Tenofov Alafenam41$73,161
EliquisApixaban70$68,380
OdefseyEmtricitab/Rilpiviri/Tenof Ala17$67,346
JanuviaSitagliptin Phosphate43$50,413
CompleraEmtricita/Rilpivirine/Tenof Df12$49,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Stribild, Descovy$68,075$1,465,129394 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Juluca$65,269$896,916304 claims
MerckJanuvia$185$50,41343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →